CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open
CSL Limited shares finished Friday’s session firmly higher, with the biotech giant benefiting from a broader rebound in Australian healthcare stocks and fresh attention on two CSL-specific threads: its ongoing on-market share buyback and the latest long-term durability data for